Side-by-side · Research reference

TesofensinevsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3AUTO-DRAFTED10/40 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Tesofensine

VIP

Primary target

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Tesofensine

VIP

Standard dose

0.25–0.5 mg / dayAstrup 2008

—

Frequency

Once daily, morning

—

Lower / starter dose

0.125 mg / day

—

Evidence basis

Phase 2b + ongoing Phase 3Astrup 2008

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

24 weeks per studied cycle

—

Form

Oral capsule

—

Timing

Morning to avoid sleep disruption

—

Half-life

~9 days (very long)

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

04Side Effects & Safety

Parameter

Tesofensine

VIP

Heart rate / BP

Dose-dependent ↑ HR + BPAstrup 2008

—

Insomnia

Dose-related; mitigate with morning timing

—

Dry mouth

Common

—

Nausea

Common

—

Mood changes

Anxiety / agitation possible

—

Cardiovascular events

Phase 3 trial monitoring; not yet FDA-cleared

—

Pregnancy / OB

Contraindicated

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Tesofensine

VIP

1. Form

Oral capsule (investigational; not commercial).

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Administration

Swallow whole with water, morning only.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Morning to mitigate insomnia. Do not dose evening.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Room temp ≤25 °C, dry place.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Caveat

Monitor BP + HR + mood. Avoid stimulants + MAOIs.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.